심장 발작 진단 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the heart attack diagnostics market size was valued at USD 12.66 billion in 2025 and estimated to grow from USD 13.72 billion in 2026 to reach USD 20.53 billion by 2031, at a CAGR of 8.39% during the forecast period (2026-2031).

This report is Segmented by Test (Electrocardiogram, Blood Tests, Angiogram (Invasive & CT Coronary), Cardiac CT/MRI, and Other Tests), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Imaging & Pathology Centers, and More), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Heart Attack Diagnostics Market Trends and Insights

Growing Global Burden of Cardiovascular Disease & Aging Population

The demographic wave is reshaping the heart attack diagnostics market. As average life expectancy rises, comorbidities such as diabetes, renal disease, and hypertension converge to create atypical symptom profiles that blunt the specificity of historical diagnostic algorithms. The European Society of Cardiology predicts atrial fibrillation prevalence will double by 2050, widening the pool of patients who require chronic rhythm monitoring to avoid sudden myocardial events. Consequently, payers now view investment in high-sensitivity assays and remote rhythm monitors as a cost-containment measure rather than a discretionary expense. Device makers are responding by embedding cloud-based analytics that stratify risk in near-real time, supporting clinical decisions long before patients reach critical-care beds.

Rising Demand for Rapid, Accurate Diagnosis in Emergency & Critical-Care Settings

Every minute lost while confirming myocardial infarction raises mortality risk. Emergency-department physicians must therefore rely on diagnostics that deliver lab-grade accuracy within a sub-10-minute window. Clinical registries show that patients lacking regular cardiology follow-up experience 24% higher in-hospital mortality, underscoring the stakes of frontline triage. Point-of-care analyzers and handheld ECG readers now incorporate AI algorithms that replicate specialist interpretation, closing skills gaps in understaffed facilities. These capabilities are especially impactful in rural hospitals, where cardiologists are scarce and air-transfer delays can exceed therapeutic time windows.

High Capital and Operating Costs of Advanced Diagnostic Systems & Consumables

Sticker prices for high-throughput chemistry analyzers or CZT-SPECT cameras can exceed USD 2 million, but the larger burden lies in recurring reagent kits, annual service contracts, and staff training. Smaller community hospitals rarely process enough specimens to recoup those costs within typical budgeting cycles. Pediatric transplant units, however, demonstrate that once-perfusion blood tests can reduce post-operative monitoring expenses tenfold without compromising safety. This example illustrates that targeted innovation can overcome cost barriers, yet scaling such solutions across broader populations remains challenging.

Other drivers and restraints analyzed in the detailed report include:

1. Continuous Innovation in Cardiac Biomarkers, Imaging & Analytics Technologies
2. Expansion of Decentralized / Point-of-Care Testing Infrastructure Worldwide
3. Stringent Regulatory Approval Pathways and Compliance Requirements

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Blood assays secured 41.02% of the heart attack diagnostics market in 2025, a position underpinned by high-sensitivity cardiac troponin I/T kits that generate definitive yes-or-no answers within the first hour of suspected infarction. That scale translates into a tangible heart attack diagnostics market size advantage, yielding USD 5.19 billion in revenues and affirming the segment as a cash-flow engine for reagent suppliers. Parallel tests such as CK-MB and myoglobin remain clinically relevant for rule-in or rule-out scenarios when baseline troponin is elevated due to chronic disease. Yet the demand profile is changing. Wearable ECG platforms are advancing at a 12.74% CAGR and are projected to overtake angiogram referrals for first-line rhythm analysis by the late-2020s. Cloud-based dashboards push continuous data streams to cardiology hubs, triggering alerts when algorithms detect ST-segment deviation or paroxysmal atrial fibrillation, a precursor to embolic myocardial events.

This growth gap underscores how the heart attack diagnostics market is migrating from episodic biomarker snapshots toward holistic, real-time physiologic surveillance. Integrated solutions combine fingerstick troponin kits, smart-patch ECG sensors, and AI-curated symptom trackers within a single subscription model. The approach appeals to health insurers because early rhythm detection can avert ambulance transfers and catheter lab admissions, both high-cost events. Imaging still holds strategic relevancy. CT coronary angiography and cardiac MRI quantify plaque burden, left-ventricular ejection fraction, and microvascular perfusion, supporting prognosis and therapy selection. Vendors capable of harmonizing biochemical, electrical, and structural data within interoperable dashboards are likely to command premium margins and lock-in users through ecosystem effects.

Complete Report Scope:

• By Test
  • Electrocardiogram (12-lead, 3-lead, Wearable)
  • Blood Tests
    • Cardiac Troponin I/T
    • CK-MB & Myoglobin
    • BNP & NT-proBNP
  • Angiogram (Invasive & CT Coronary)
  • Cardiac CT/MRI
  • Other Tests
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Imaging & Pathology Centers
  • Home-based & Tele-cardiology Settings
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America led global revenue with a 35.02% share in 2025, fueled by mature payer systems that reimburse novel biomarkers and digital ECG analytics without lengthy coverage lags. The United States has embedded troponin turnaround-time targets into quality metrics tied to hospital payment, ensuring that devices capable of sub-10-minute results secure favorable placement. Canada's single-payer structure stresses outcomes-based procurement, promoting multi-platform solutions that reduce total admissions rather than stand-alone tests. Clinical practice guidelines issued by the American Heart Association and the European Society of Cardiology are widely adopted, smoothing cross-border clinical pathways.

Europe contributes a substantial volume of procedures through universal coverage and rigorous evidence-based approval processes. Germany's Netzwerk Herzzentren has standardized biomarker protocols, while the United Kingdom's National Health Service is trialing AI-enabled ECG triage in community clinics. Adoption across Italy, France, and Spain accelerates where domestic producers partner with public hospitals to localize production of consumables, thereby sidestepping supply-chain constraints. Regulatory convergence under the European Medical Device Regulation continues to raise compliance costs but also harmonizes market access across member states.

Asia-Pacific is the fastest-growing territory, expanding at a 10.41% CAGR from 2026 to 2031. China's Healthy China 2030 blueprint earmarks cardiovascular illness as a national priority, pushing public hospitals to deploy high-sensitivity troponin and low-radiation CT angiography in prefecture-level cities. Japan's super-aging demographic accelerates demand for ambulatory cardiac monitors that can upload data to cloud repositories compliant with stringent privacy laws. India's Ayushman Bharat scheme widens insurance coverage, encouraging public-private partnerships to distribute point-of-care troponin kits into district hospitals. Collectively, these initiatives enlarge the heart attack diagnostics market, but vendors must tailor price points and service models to heterogeneous payer structures.

Across the Middle East & Africa, Gulf Cooperation Council states invest in Western-standard tertiary centers that install state-of-the-art biomarker analyzers. In contrast, sub-Saharan health ministries favor portable diagnostics that function in low-infrastructure settings. South American nations grapple with currency volatility; however, Brazil's Unified Health System funds nationwide chest-pain units equipped with handheld ECG devices. These dynamics illustrate that while North America sets revenue benchmarks, long-term volume growth increasingly hinges on strategies tuned to emerging-market needs.

1. Abbott Laboratories
2. Roche
3. Siemens Healthineers
4. GE Healthcare
5. Koninklijke Philips
6. Beckman Coulter (Danaher)
7. bioMerieux
8. QuidelOrtho
9. Hitachi
10. Schiller
11. Toshiba Electronic Devices & Storage
12. Midmark
13. WuXi Diagnostics
14. Becton Dickinson & Co.
15. Nihon Kohden Corp.
16. AliveCor
17. PerkinElmer
18. Sysmex Corp.
19. Thermo Fisher Scientific
20. AstraZeneca plc (Dx collaborations)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Global Burden of Cardiovascular Disease & Aging Population
  • 4.2.2 Rising Demand for Rapid, Accurate Diagnosis In Emergency & Critical-Care Settings
  • 4.2.3 Continuous Innovation in Cardiac Biomarkers, Imaging & Analytics Technologies
  • 4.2.4 Expansion Of Decentralized/Point-Of-Care Testing Infrastructure Worldwide
  • 4.2.5 Favourable Government Initiatives and Reimbursement for Early MI Detection
  • 4.2.6 Increasing Healthcare Expenditure and Adoption Across Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 High Capital and Operating Costs of Advanced Diagnostic Systems & Consumables
  • 4.3.2 Stringent Regulatory Approval Pathways and Compliance Requirements
  • 4.3.3 Shortage of Skilled Healthcare Professionals Trained In Cardiac Diagnostics
  • 4.3.4 Limited Accessibility and Reimbursement in Low-Resource Settings
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Bargaining Power of Buyers
  • 4.5.2 Bargaining Power of Suppliers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Test
  • 5.1.1 Electrocardiogram (12-lead, 3-lead, Wearable)
  • 5.1.2 Blood Tests
    • 5.1.2.1 Cardiac Troponin I/T
    • 5.1.2.2 CK-MB & Myoglobin
    • 5.1.2.3 BNP & NT-proBNP
  • 5.1.3 Angiogram (Invasive & CT Coronary)
  • 5.1.4 Cardiac CT/MRI
  • 5.1.5 Other Tests
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Ambulatory Surgical Centers
  • 5.2.3 Diagnostic Imaging & Pathology Centers
  • 5.2.4 Home-based & Tele-cardiology Settings
  • 5.2.5 Other End Users
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 F. Hoffmann-La Roche Ltd
  • 6.3.3 Siemens Healthineers
  • 6.3.4 GE HealthCare
  • 6.3.5 Koninklijke Philips N.V.
  • 6.3.6 Beckman Coulter (Danaher)
  • 6.3.7 bioMrieux SA
  • 6.3.8 QuidelOrtho Corporation
  • 6.3.9 Hitachi Ltd.
  • 6.3.10 Schiller AG
  • 6.3.11 Toshiba Electronic Devices & Storage
  • 6.3.12 Midmark Corporation
  • 6.3.13 WuXi Diagnostics
  • 6.3.14 Becton Dickinson & Co.
  • 6.3.15 Nihon Kohden Corp.
  • 6.3.16 AliveCor Inc.
  • 6.3.17 PerkinElmer Inc.
  • 6.3.18 Sysmex Corp.
  • 6.3.19 Thermo Fisher Scientific Inc.
  • 6.3.20 AstraZeneca plc (Dx collaborations)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment